|
1
|
Napier KJ, Scheerer M and Misra S:
Esophageal cancer: A review of epidemiology, pathogenesis, staging
workup and treatment modalities. World J Gastrointest Oncol.
6:112–120. 2014. View Article : Google Scholar
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zeng H, Zheng R, Zhang S, Zuo T, Xia C,
Zou X and Chen W: Esophageal cancer statistics in China, 2011:
Estimates based on 177 cancer registries. Thorac Cancer. 7:232–237.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y,
Ueda J, Wei W, Inoue M and Tanaka H: Epidemiology of esophageal
cancer in Japan and China. J Epidemiol. 23:233–242. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pennathur A, Gibson MK, Jobe BA and
Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Soussi T: The p53 pathway and human
cancer. Brit J Surg. 92:1331–1332. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vousden KH and Lane DP: p53 in health and
disease. Nat Rev Mol Cell Biol. 8:275–283. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
da Silva GN, Evangelista AF, Magalhães DA,
Macedo C, Búfalo MC, Sakamoto-Hojo ET, Passos GA and Salvadori DM:
Expression of genes related to apoptosis, cell cycle and signaling
pathways are independent of TP53 status in urinary bladder cancer
cells. Mol Biol Rep. 38:4159–4170. 2011. View Article : Google Scholar
|
|
11
|
Cardin R, Piciocchi M, Tieppo C, Maddalo
G, Zaninotto G, Mescoli C, Rugge M and Farinati F: Oxidative DNA
damage in Barrett mucosa: Correlation with telomeric dysfunction
and p53 mutation. Ann Surg Oncol. 20 (Suppl 3):S583–S589. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Di Agostino S, Strano S and Blandino G:
Gender, mutant p53 and PML: A growing ‘affaire’ in tumor
suppression and oncogenesis. Cell Cycle. 12:1824–1825. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Greenblatt MS, Bennett WP, Hollstein M and
Harris CC: Mutations in the p53 tumor suppressor gene: Clues to
cancer etiology and molecular pathogenesis. Cancer Res.
54:4855–4878. 1994.PubMed/NCBI
|
|
14
|
Song Y, Li L, Ou Y, Gao Z, Li E, Li X,
Zhang W, Wang J, Xu L, Zhou Y, et al: Identification of genomic
alterations in oesophageal squamous cell cancer. Nature. 509:91–95.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang K, Chen L, Zhang J, Wu Z, Lan L,
Wang L, Lu B and Liu Y: Elevated p53 expression levels correlate
with tumor progression and poor prognosis in patients exhibiting
esophageal squamous cell carcinoma. Oncol Lett. 8:1441–1446. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Okumura H, Kita Y, Yokomakura N, Uchikado
Y, Setoyama T, Sakurai H, Omoto I, Matsumoto M, Owaki T, Ishigami S
and Natsugoe S: Nuclear expression of 14-3-3 sigma is related to
prognosis in patients with esophageal squamous cell carcinoma.
Anticancer Res. 30:5175–5179. 2010.PubMed/NCBI
|
|
17
|
Zhao Z, Wang P, Gao Y and He J: The high
expression instead of mutation of p53 is predictive of overall
survival in patients with esophageal squamous-cell carcinoma: A
meta-analysis. Cancer Med. 6:54–66. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Murata A, Baba Y, Watanabe M, Shigaki H,
Miyake K, Karashima R, Imamura Y, Ida S, Ishimoto T, Iwagami S, et
al: p53 immunohistochemical expression and patient prognosis in
esophageal squamous cell carcinoma. Med Oncol. 30:7282013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Taghavi N, Biramijamal F, Sotoudeh M,
Moaven O, Khademi H, Abbaszadegan MR and Malekzadeh R: Association
of p53/p21 expression with cigarette smoking and prognosis in
esophageal squamous cell carcinoma patients. World J Gastroenterol.
16:4958–4967. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nenutil R, Smardova J, Pavlova S,
Hanzelkova Z, Muller P, Fabian P, Hrstka R, Janotova P, Radina M,
Lane DP, et al: Discriminating functional and non-functional p53 in
human tumours by p53 and MDM2 immunohistochemistry. J Pathol.
207:251–259. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Halling KC and Kipp BR: Fluorescence in
situ hybridization in diagnostic cytology. Hum Pathol.
38:1137–1144. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tafe LJ, Allen SF, Steinmetz HB, Dokus BA,
Cook LJ, Marotti JD and Tsongalis GJ: Automated processing of
fluorescence in-situ hybridization slides for HER2 testing in
breast and gastro-esophageal carcinomas. Exp Mol Pathol.
97:116–119. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Egashira A, Morita M, Yoshida R, Saeki H,
Oki E, Sadanaga N, Kakeji Y, Tsujitani S and Maehara Y: Loss of p53
in esophageal squamous cell carcinoma and the correlation with
survival: Analyses of gene mutations, protein expression, and loss
of heterozygosity in Japanese patients. J Surg Oncol. 104:169–175.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bellini MF, Cadamuro AC, Succi M, Proenca
MA and Silva AE: Alterations of the TP53 gene in gastric and
esophageal carcinogenesis. J Biomed Biotechnol. 2012:8919612012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Edge SB and Compton CC: The American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fagundes RB, Melo CR, Pütten AC, Moreira
LF and de Barros SG: p53 immunoexpression: An aid to conventional
methods in the screening of precursor lesions of squamous
esophageal cancer in patients at high-risk? Cancer Detect Prev.
29:227–232. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Muller PA and Vousden KH: p53 mutations in
cancer. Nat Cell Biol. 15:2–8. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yen CC, Tsao YP, Chen PC, Wu YC, Liu JH,
Pan CC, Liu CY, Tzeng CH, Chen PM, Chen YJ, et al: PML protein as a
prognostic molecular marker for patients with esophageal squamous
cell carcinomas receiving primary surgery. J Surg Oncol.
103:761–767. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang L, Yu X, Li J, Zhang Z, Hou J and Li
F: Prognostic significance of p53 expression in patients with
esophageal cancer: A meta-analysis. BMC Cancer. 16:3732016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Melling N, Norrenbrock S, Kluth M, Simon
R, Hube-Magg C, Steurer S, Hinsch A, Burandt E, Jacobsen F, Wilczak
W, et al: p53 overexpression is a prognosticator of poor outcome in
esophageal cancer. Oncol Lett. 17:3826–3834. 2019.PubMed/NCBI
|
|
31
|
Yamamoto S, Yashima K, Kawata S, Hosoda K,
Tamoto A, Ikebuchi Y, Matsumoto K, Kawaguchi K, Harada K, Murawaki
Y and Isomoto H: Frequent aberrant p53 and Fhit expression in
endoscopically resected superficial hypopharyngeal cancer and
esophageal cancer. Oncol Lett. 14:587–592. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Niyaz M, Turghun A, Ping ZH, Zhu Z,
Sheyhedin I, Ren C and Awut I: TP53 gene deletion in esophageal
cancer tissues of patients and its clinical significance. Mol Med
Rep. 7:122–126. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Graesslin O, Chantot-Bastaraud S,
Lorenzato M, Birembaut P, Quéreux C and Daraï E: Fluorescence in
situ hybridization and immunohistochemical analysis of p53
expression in endometrial cancer: Prognostic value and relation to
ploidy. Ann Surg Oncol. 15:484–492. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Davelaar AL, Calpe S, Lau L, Timmer MR,
Visser M, Ten Kate FJ, Parikh KB, Meijer SL, Bergman JJ, Fockens P
and Krishnadath KK: Aberrant TP53 detected by combining
immunohistochemistry and DNA-FISH improves Barrett's esophagus
progression prediction: A prospective follow-up study. Genes
Chromosomes Cancer. 54:82–90. 2015. View Article : Google Scholar : PubMed/NCBI
|
